Innoviva Comprehensive Income 2010-2024 | INVA

Innoviva comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Innoviva Annual Comprehensive Income
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $0
2018 $-0
2017 $-0
2016 $0
2015 $-0
2014 $-0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Innoviva Quarterly Comprehensive Income
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30 $-0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $-0
2018-09-30 $-0
2018-06-30 $-0
2018-03-31 $-0
2017-12-31 $-0
2017-09-30 $-0
2017-06-30
2017-03-31 $-0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $-0
2015-12-31 $-0
2015-09-30 $0
2015-06-30 $-0
2015-03-31 $-0
2014-12-31 $-0
2014-09-30 $-0
2014-06-30 $4
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $-0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $-0
2012-03-31 $-0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $-0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $-0
2010-03-31 $-0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.259B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Pfizer (PFE) United States $148.702B 10.17
Sanofi (SNY) $128.465B 11.64